Pharmaceutical intermediates
Nilotinib Intermediates
3 pharmaceutical intermediates for Nilotinib. Indication: Chronic Myeloid Leukemia (CML); Accelerated Phase of Myeloid Leukemia; Chronic Myelogenous Leukemia (CML).
About Nilotinib
- Originator
- Novartis Pharmaceuticals Corp
- Indication
- Chronic Myeloid Leukemia (CML); Accelerated Phase of Myeloid Leukemia; Chronic Myelogenous Leukemia (CML)
- Approved Date
- 10/29/2007
Available intermediates
3 intermediates currently listed for Nilotinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 3-[(Aminoiminomethyl)amino] -4-methylbenzoic acid ethyl ester mononitrate | 641569-96-2 | / | / |
| 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid | 641569-94-0 | / | / |
| 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline | 641571-11-1 | / | / |
Building toward Nilotinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →